547 results on '"Rix, Uwe"'
Search Results
152. Abstract A71: Differential proteome-wide target profiles of clinical poly(ADP-ribose) polymerase inhibitors in breast cancer
153. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.
154. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer
155. Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
156. Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies
157. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides
158. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
159. Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations
160. Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML
161. Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
162. Abstract 1750: Combined blockade of Aurora A and JAK2 kinase is highly effective at inhibiting malignant transformation
163. Abstract 2414: Overexpression of PAXIP1 potentiates WEE1 inhibitor action in lung cancer cells
164. Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation
165. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
166. GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
167. A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL
168. A Miniaturized Chemical Proteomic Approach for Target Profiling of Clinical Kinase Inhibitors in Tumor Biopsies
169. Abstract 5038: Probing network fragilities in neuroblastoma by synergistic drug combinations.
170. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
171. Abstract IA2: Network models in oncogene-addicted lung cancer
172. Systems biology analysis of protein-drug interactions
173. An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
174. KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
175. A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib
176. ChemInform Abstract: Modification of Post-PKS Tailoring Steps Through Combinatorial Biosynthesis.
177. MASPECTRAS 2: An integration and analysis platform for proteomic data
178. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
179. Dasatinib in solid tumors
180. Acid Elution and One-Dimensional Shotgun Analysis on an Orbitrap Mass Spectrometer: An Application to Drug Affinity Chromatography
181. Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells
182. Target profiling of small molecules by chemical proteomics
183. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
184. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
185. Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.
186. Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib
187. Cytotoxic Activities of New Jadomycin Derivatives (I).
188. Functional Analyses of Oxygenases in Jadomycin Biosynthesis and Identification of JadH as a Bifunctional Oxygenase/Dehydrase
189. Cytotoxic Activities of New Jadomycin Derivatives
190. The Oxidative Ring Cleavage in Jadomycin Biosynthesis: A Multistep Oxygenation Cascade in a Biosynthetic Black Box
191. Identification of the Function of Gene lndM2 Encoding a Bifunctional Oxygenase-Reductase Involved in the Biosynthesis of the Antitumor Antibiotic Landomycin E by Streptomyces globisporus 1912 Supports the Originally Assigned Structure for Landomycinone
192. Generation of New Landomycins by Combinatorial Biosynthetic Manipulation of the LndGT4 Gene of the Landomycin E Cluster in S. globisporus
193. Compound Immobilization and Drug-Affinity Chromatography.
194. Urdamycin L: A Novel Metabolic Shunt Product that Provides Evidence for the Role of the urdM Gene in the Urdamycin A Biosynthetic Pathway of Streptomyces fradiae TUE 2717.
195. Modification of post-PKS tailoring steps through combinatorial biosynthesis
196. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.
197. Systems biology analysis of protein-drug interactions.
198. Target profiling of small molecules by chemical proteomics.
199. Identification of the Function of Gene lndM2 Encoding a Bifunctional Oxygenase-Reductase Involved in the Biosynthesis of the Antitumor Antibiotic Landomycin E by Streptomyces globisporus 1912 Supports the Originally Assigned Structure for Landomycinone.
200. GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.